Objective: To characterize a long-term model of recovery from critical illness, with particular emphasis on cardiorespiratory, metabolic, and muscle function. Design: Randomized controlled animal study. Setting: University research laboratory. Subjects: Male Wistar rats. Interventions: Intraperitoneal injection of the fungal cell wall constituent, zymosan or n-saline. Measurements and Main Results: Following intervention, rats were followed for up to 2 weeks. Animals with zymosan peritonitis reached a clinical and biochemical nadir on day 2. Initial reductions were seen in body weight, total body protein and fat, and muscle mass. Leg muscle fiber diameter remained subnormal at 14 days with evidence of persisting myonecrosis, even though gene expression of regulators of muscle mass (e.g., MAFbx, MURF1, and myostatin) had peaked on days 2-4 but normalized by day 7. Treadmill exercise capacity, forelimb grip strength, and in vivo maximum tetanic force were also reduced. Food intake was minimal until day 4 but increased thereafter. This did not relate to appetite hormone levels with early (6 hr) rises in plasma insulin and leptin followed by persisting subnormal levels; ghrelin levels did not change. Serum interleukin-6 level peaked at 6 hours but had normalized by day 2, whereas interleukin-10 remained persistently elevated and high-density lipoprotein cholesterol persistently depressed. There was an early myocardial depression and rise in core temperature, yet reduced oxygen consumption and respiratory exchange ratio with a loss of diurnal rhythmicity that showed a gradual but incomplete recovery by day 7. Conclusions:This detailed physiological, metabolic, hormonal, functional, and histological muscle characterization of a model of critical illness and recovery reproduces many of the findings reported in human critical illness. It can be used to assess putative therapies that may attenuate loss, or enhance recovery, of muscle mass and function. (Crit Care Med 2015; 43:e84-e96)
I nsults such as infection, trauma, and hemorrhage can trigger a dysregulated release of proinflammatory and antiinflammatory mediators that, through a final common pathway, may progress to multiple organ failure and death. In survivors, severe inflammation, critical illness neuromyopathy, catabolic loss of protein, metabolic modifications, and prolonged immobility result in loss of muscle mass and weakness. Recovery of muscle function can take many months and may be incomplete (1) (2) (3) . Interventions that clearly ameliorate and/ or reverse this muscle dysfunction are lacking. This is, in part, due to the dearth of good preclinical models that can evaluate both pathophysiologic mechanisms and putative therapies.
Animal, particularly rodent, models of critical illness abound. However, they generally focus on short-term outcomes ranging from hours to a few days (4) . Models examining the prolonged recovery phase of critical illness are rare, despite inadequate recovery being increasingly recognized as having a major negative impact upon long-term quality of life (2, 5) . Muscle biopsies from affected patients confirm significant atrophy and wasting (6) (7) (8) (9) (10) , though direct inferences from single-fiber level pathology to functional tests of muscle strength and fatigue are limited. Experiments utilizing in situ muscle force generation by direct nerve stimulation have been reported (11, 12) , but also have limitations, being preterminal and/or requiring deep anesthesia.
Zymosan, a cell wall glucopolysaccharide of the fungus Saccharomyces cerevisae, signals via Toll-like receptor-2 to induce a nonbacterial, nonendotoxic sterile local inflammatory stimulus with sustained release of lysosomal enzymes, reactive oxygen species, and cytokines, triggering a systemic inflammatory, sepsis-like response (13) . When suspended in paraffin and injected intraperitoneally (IP), zymosan produces a prolonged peritonitis (14) (15) (16) . Clinical features initially resemble bacterial sepsis with piloerection, tachycardia, fever, and reduced spontaneous movement. Catabolism, evidenced by reduced body mass and muscle atrophy, occurs after 5 days or so, followed by clinical recovery with resumption of feeding and restoration of lost body weight and muscle mass (16) .
The aim of our study was to develop, comprehensively characterize, and validate a long-term model of rodent critical illness and recovery, based on zymosan peritonitis, which would simulate the metabolic and physiological responses seen in chronic critical illness in humans. We wished to demonstrate initial weight loss, muscle weakness, and anorexia that would recover in line with clinical recovery. We describe accompanying changes in total body oxygen consumption and respiratory exchange ratio (RER), overall body composition, hemodynamics, muscle mass, function, and histology during the recovery phase from critical illness. Importantly, we also describe a new electromyographic technique for sequential assessment of muscle function.
MATERIALS AND METHODS

Animal Model
Male Wistar rats (Charles River, Margate, United Kingdom) of approximately 300 g body weight were singly housed for at least 72 hours preinduction of peritonitis. They had free access to water and standard rat chow (Harlan Teklad, Madison, WI) containing 18% protein and 5% fat. Ambient temperature was controlled between 19°C and 23°C and humidity at 55% ± 10%. Lights were automatically turned on and off at 07:00 and 19:00 hours, respectively. Studies were performed under U.K. Home Office project license and guidelines under the Animals (Scientific Procedures) Act 1986. Ethical approval was given by the University College London Ethics Committee.
Zymosan A (Sigma Aldrich, St. Louis, MO), mixed with liquid paraffin (Merck, Darmstadt, Germany) to a concentration of 25 mg/mL (14) , was homogenized at 24,000 rpm for 5 minutes, sterilized in boiling water for 90 minutes, and stored at 4°C until required. Zymosan (30 mg/100 g body mass) was administered IP via a 19G needle under brief isoflurane anesthesia. Sham-treated animals received an equivalent volume of saline injection, whereas naïve, nonoperated animals received no IP injection.
Animals were checked at least four times daily and scored to assess insult severity ( Table 1 ) (17) . When clinical scores had returned to normal, they were scored once daily. Any animal displaying signs of distress, or an inability to move, right itself or respond to external stimuli, was culled. Some animals did not display any clinical signs of illness (thus having a clinical severity score of 0), or lose body mass, and had normal or nearnormal food intake during the course of the study. These animals were excluded from subsequent analysis.
Temporal Analysis
Procedures and tests described below were not all performed on the same animals. Apart from body weight and food intake, which were measured daily, the tests below were performed at up to eight timepoints: 6 hours and 1, 2, 4, 7, 10, 12, and 14 days post administration of zymosan or n-saline. Food Intake, body Mass, and Tissue Mass Body weight and food intake were measured daily at 08:00 hours. Care was taken to collect and account for discarded food. After culling, gastrocnemius and soleus muscles were rapidly dissected and weighed before freezing in liquid nitrogen for subsequent biochemical analysis (see later).
Core Temperature
Body temperature was measured via a rectal probe attached to a Homeothermic Monitor (Harvard Apparatus, Edenbridge, Kent, United Kingdom). 
Exercise Capacity and Muscle Function Tests
Forelimb Grip Strength
Muscle function tests were performed using a grip strength meter (Linton Instrumentation, Diss, Norfolk, United Kingdom) on days 0, 2, 5, 8, and 12. Familiarization with the grip strength meter was ensured over a week prior to study commencement. The forelimbs were placed on a T-bar attached to a force transducer shaft connected to a peak amplifier and allowed to flex before being pulled horizontally away gently by the base of the tail (18) . The maximum grip force exerted by the rat until it released its grip was recorded. This was repeated five times for each animal (at 20-s intervals). The mean maximum peak force (in grams) was calculated from the top three values obtained (18) .
Treadmill
Exercise capacity was determined using a rodent treadmill (Harvard Apparatus) at baseline (prior to sepsis induction) and then repeated on days 2, 4, 7, and 14. Animals were preacclimatized to the treadmill in five sessions over 2 days, with increasing belt speed exposure over a 5-minute interval. Formal assessment was then made by increments in belt speed rate (by 5 cm/s every 2 min) until animal fatigue occurred. This was determined by the inability to keep up with the belt speed despite a mild electric shock deterrent applied to the hind legs when the animals touched the metal grid immediately behind the belt. If this occurred more than three times at one speed (19) , the protocol was stopped. Performance time (in minutes) was used as a marker of exercise capacity.
Hindlimb Myography
This was performed under isoflurane anesthesia with animals placed supine and temperature maintained at 37°C on a purpose-built rig (Harvard Apparatus) on days 0, 2, 4, 7, and 14. Alternate hindlimbs, from which the fur was shaved, were tested at alternate timepoints. The hindlimb was fixed into position so that two needle electrodes could be inserted into the posterior muscle bulk. The electrodes provided an electrical stimulus via PowerLab 4/35 (ADInstruments, Oxford, United Kingdom) resulting in plantar flexion, with a fixed length chain connecting the foot to a force transducer measuring the force generated. The mean of three measures of force (newton) was taken at increasing single stimuli between 1 and 15 V. This was followed by continuous submaximal electrical stimulation (electrical pulses at 12 V for 0.05 s set at 40 Hz) for 3.5 minutes to generate tetany. This enabled calculation of the submaximal tetanic force at the start of the fatigue protocol and the fatigue index at 2 minutes (20) . This index was derived from the proportion of tetanic force maintained at 2 minutes compared with the initial tetanic force during the fatigue test. Examples of traces obtained are shown in Supplementary Figure 1 (Supplemental Digital Content 4, http://links.lww.com/CCM/B183). Following myography, animals recovered fully from anesthesia and a full range of movement was observed in the tested hindlimb.
blood Cytokine, Gut Hormone, and Adipokine Measurements
Blood samples were taken after culling either by decapitation (truncal blood: mixed arterial-venous) or by cardiac puncture and divided equally into two chilled lithium-heparin test tubes, one of which contained 5 mg 4-(2-amino-ethyl)benzenesulfonylfluoride hydrochloride (Sigma Aldrich) and 100 μL aprotinin (10,000 kIU/mL; Sigma Aldrich) for analysis of gut hormone levels (21) . Both tubes were spun immediately at 4,000 g for 15 minutes and the plasma aliquoted into plastic Eppendorf tubes, one of which contained 25 μL 1 M HCl, to which 500 μL plasma from the "gut hormone" test tube was added for preservation of active ghrelin. The Eppendorf tubes were snap frozen in liquid nitrogen before storage at -80°C. Plasma biochemistry was analyzed by The Doctors Laboratory, London, United Kingdom, and the Department of Clinical Biochemistry, Charing Cross Hospital, London, United Kingdom, using standard analyzers. Gut hormones, leptin, and cytokines were measured in duplicate using rat-specific multiplex bead-based assays (Millipore, Billerica, MA). Readings greater than 2 sds from the mean for each gut hormone (two of 47) were not included in the final analysis as these are likely due to methodological issues with the multiplex assay.
In Vivo Metabolic behavior
The Comprehensive Laboratory Animal Monitoring System (CLAMS) with Oxymax for Windows software (Columbus Instruments, Columbus, OH) was used to measure oxygen consumption (Vo 2 ) and carbon dioxide production (Vco 2 ) in naïve, sham-operated, and zymosan-treated rats. CLAMS is an opencircuit system where a continuous supply of room air (set at 400 mL/min) is delivered to, in our laboratory, four tightly sealed cages. Gas sensors were calibrated before each study against known concentrations of oxygen (20.5%) and carbon dioxide (0.05%). Oxygen and Co 2 concentrations were measured from air sampled from each cage for 2 minutes in turn and of room air after every fourth sample. The rats remained in the metabolic carts for 7 days, apart from a 5-to 10-minute period each morning when they were weighed and their cages cleaned.
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Cardiac Function
Under brief anesthesia, spontaneously breathing rats with shaved chests underwent echocardiography (Vivid 7 Dimension; GE Healthcare, Bedford, United Kingdom) with a 14-MHz probe at 0-to 2-cm depth, as described (22) . Heart rate and respiratory rate were measured from these recordings. Pulsed-wave Doppler measured aortic flow velocity in the aortic arch, with color Doppler confirming the direction of flow. Stroke volume was calculated as the product of velocitytime integral of each waveform and aortic cross-sectional area, assuming an aortic diameter of 0.28 cm (23) . Studies were performed sequentially in the same animals before intraperitoneal injection and on days 2, 4, 7, and 14. In separate studies, echocardiography was performed at 6 or 24 hours post injection just prior to culling for blood and tissue sampling.
Rodent body Composition
In some studies, rats were culled on day 12 by cervical dislocation under isoflurane anesthesia. Gastrointestinal tract contents were cleared manually and any intra-abdominal fluid removed. The carcass was frozen at -80°C, before being dissolved in 1 mL 3M KOH in 65% ethanol (VWR, Radnor, PA) per 1 g carcass mass, sealed in a plastic pot, and placed in an oven at 70°C for 5 days. The bones were removed by passing the liquid through a sieve, and the total amount of liquid was then made up to 1,000 mL by addition of 100% ethanol. From this, a sample of fluid was removed and stored for analysis of protein and fat content. Carcass protein and fat content were determined using a modified Lowry Protein Assay kit (Thermo Scientific, Rockford, IL) and a glycerol assay (Randox, Crumlin, Northern Ireland), respectively. The glycerol assay kit included all reagents with the exception of the glycerol standard, for which 1 M glycerol (VWR) was used. . β-actin was used to normalize expression levels of genes of interest. Primers were designer using Primer 3 software from gene sequences obtained from GenBank. Primer specificity was determined using a BLAST search.
RNA Isolation, Complementary DNA Synthesis, and Real-Time Polymerase Chain Reaction
Muscle Histology
Animals culled on days 2, 7, and 14 had gastrocnemius and soleus muscle dissected and rapidly frozen in 2-methylbutyrate (Merck) cooled with liquid nitrogen before storage at -80°C until sectioning. These animals did not undergo exercise training nor the tests of muscle function described above. Serial cryostat sections were cut at 8 μm (OTF [codename of Cryostat device], Bright Instruments, Huntingdon, United Kingdom) and embedded in optimal cutting temperature compound but known as OCT (Sakura Finatek, Tatcham, United Kingdom).
Staining with hematoxylin and eosin (H&E) was performed on a ST5020 Multistainer (Leica Biosystems, Milton Keynes, United Kingdom). Muscle pathology was assessed by a neuropathologist blinded to group and sampling time. H&E-stained sections were assessed semiquantitatively for necrosis, regeneration, and atrophy in five randomly selected high-power fields on a Leica bright-field microscope: 0, 1-3 (mild), 4-9 (moderate), and at least 10 and/or focal clustered or circumscribed pathology (marked). Assessment of regenerating fibers was limited to recognition of early-phase regeneration (intensely basophilic small fibers with large central nuclei resembling myotubes) and late-phase regeneration (mature-sized fibers with internalized nuclei). It was not possible to reliably distinguish regenerating fibers between these two phases from fibers undergoing atrophy as both can appear slightly basophilic and granular in H&Estained sections. Inflammation was assessed for its cellular type, location (perimysium, endomysium, and/or blood vessels), and graded semiquantitatively (0 none, 1 mild, 2 moderate, and 3 severe). Intramuscular motor nerves were not assessed.
For cell morphometry, myofiber size was assessed by measuring fiber diameter (FD). Immunohistochemical labeling with α sarcoglycan (Leica NCL-l-a-SARC, Novocastra), a muscle-specific membrane protein (1:200 concentration, 1-hr incubation period at room temperature), was performed using an automated staining machine (IntelliPATH FLX; A. Menarini Diagnostics, Wokingham, United Kingdom). Horseradish peroxidase-conjugated streptavidin complex and diaminobenzidine were used as chromogen. Images were digitized on a LEICA SCN400 scanner for subsequent digital image analysis using Definiens. Each section was screened prior to analysis to ensure inclusion of regions sectioned optimally in the transverse plane and to exclude regions of perimysial connective tissue, focal folds, and other artifacts. Mean normal fiber size range in naïve gastrocnemius and soleus muscle was established by measuring lesser FD in approximately 100 optimally transversely sectioned fibers in random fields. In all samples, myofibers less than 15 micron diameter with angular or polygonal profiles were designated atrophic. Fibers adjacent to myotendinous insertions show increased fiber size variability and internal nuclei as a normal histological feature and were therefore excluded from the atrophy and regeneration count.
Statistical Analysis
Data were checked for normality using the Shapiro-Wilk test and presented as mean ± sd. For comparisons between unpaired groups for change in body mass, food intake, and area under the curve from the metabolic carts, the Kruskal-Wallis test with Dunn post hoc analysis was used. Unpaired Student t tests were performed for comparison of the change in body composition between zymosan and naïve groups. Two-way analysis of variance with post hoc Bonferroni analysis was performed for statistical analysis of biochemical, gut hormone, cytokine, echocardiography, atrogene and muscle strength, and FD measurements. Statistical analyses were performed with GraphPad Prism computer software (version 5.00 for Windows; GraphPad Software, San Diego, CA). Statistical significance was set at the 5% level.
RESULTS
Details of animal numbers tested in the separate studies are shown in Supplementary Table 2 (Supplemental Digital Content 6, http://links.lww.com/CCM/B185). No naïve or sham-treated animal died prematurely. In accord with previous reports (14), of the 150 zymosan-treated animals, 15 were excluded as they were not clinically affected, while one had a fluctuating course of weight loss and intermittent partial weight gain without ever surpassing its original body mass and so was also excluded a priori. Two animals were culled prematurely due to illness severity. The 24-hour clinical severity score was similar between groups of zymosan-treated animals culled at 24 hours and days 2, 4, 7, or 12 (p = 0.40). Naïve and sham groups remained healthy throughout (score 0). Despite receiving the same insult, macroscopic appearances of the peritoneal cavity in zymosan-treated animals varied greatly on postmortem examination, from normal to showing considerable fibrous tethering of the visceral organs, small abscesses, and serous fluid. Although not formally assessed, these changes appeared to correlate with both clinical severity and recovery of body mass.
Food Intake, body Mass, and Impact of Clinical Severity
The initial body mass preinsult (range, 274-333 g) was similar between groups, stratified by either intervention or day culled. In naïve and sham animals, body weight increased in a similar, nearlinear fashion (Fig. 1A) , with both groups gaining 29% at 12 days. Animals receiving zymosan initially lost weight, reaching a nadir of 12% weight loss at day 4. They regained baseline weight by day 7 and, by day 12, had increased body weight by 13.3%. Loss of weight at day 4 was severity dependent (Fig. 1B) . Cumulative food intake (Fig. 1C) was significantly reduced in the zymosan group (p < 0.001 compared with naïve and sham animals) with daily intake being significantly lower until day 6. Animals with a 24-hour severity score at least 1 (range, 1-4; mean, 3) had a significantly lower food intake over 12 days compared with clinically unaffected (score 0) zymosan-treated animals (Fig. 1D) .
Muscle Mass and body Composition
Over the first week, zymosan-treated animals (n = 8) had reduced muscle mass with significant reductions in wet gastrocnemius mass at days 2, 4, and 7 and soleus mass at days 4 and 7 (Fig. 2, A and B) . Total body protein content ( Fig. 2C) and, in particular, fat content (Fig. 2D) were significantly lower in the zymosan group.
Regulators of Skeletal Muscle Mass
The messenger RNA (mRNA) levels of several critical regulators of skeletal muscle mass (atrogenes) were determined in naïve and zymosan-treated animals, including myostatin, a musclesecreted protein that negatively regulates skeletal muscle mass (25, 26) ; MAFbx and MuRF1, two E3-ubiquitin ligases involved in the control of ubiquitin-proteasome-dependent proteolysis (27, 28) ; microtubule-associated protein 1 light chain 3 β (LC3b), an important regulator of the autophagy-lysosome-dependent pathway (29) ; and cathepsins B and L, two lysosomal proteases (29, 30) ( Fig. 3) . Zymosan induced a marked increase in the mRNA level of these genes, the expression of which peaked at day 2 (MAFbx, MuRF1, LC3b, cathepsin B, and cathepsin L) or day 4 (myostatin). Transcript levels returned to baseline values by day 7.
Metabolic Monitoring
In separate 7-day experiments, oxygen uptake and carbon dioxide production were measured Figure 1 . Effect of zymosan on body mass and food intake. Rats were studied at 1, 2, 4, and 7 d after IP injection of zymosan (30 mg/100 g body mass), n-saline (sham), or no injection (naïve). Zymosan-injected animals with a clinical score of 0 at 24 hr were excluded from analysis. Change in body mass (A) and cumulative food intake (C) are shown (zymosan-injected animals with a clinical score of zero at 24 hr were excluded from analysis.) Data are expressed as mean (± sd). n = 4 (naïve); n = 4 (sham); n = 5-8 (zymosan). Also shown are the effects of zymosan on 12-d body mass and food intake according to clinical score at 24 hr. Change in body mass (b) and total food intake (D) are shown for naïve animals (n = 5) and zymosan-treated animals with a clinical severity score of either 0 (n = 8) or 1-4 (n = 22). Data are expressed as median ± interquartile range (box) and range (whiskers). **p < 0.01 vs naïve; ***p < 0.0001 vs naïve; + p < 0.05 vs score 0; ++ p < 0.01 vs score 0.
www.ccmjournal.org e89 continually in metabolic cages, from which the RER was calculated ( Fig. 4) . Naïve and sham animals had virtually identical traces with clear diurnal variation. In contrast, zymosan induced a rapid and marked depression of Vo 2 and Vco 2 with a significant fall in RER that did not recover until days 5 and 6. Notably, there was complete loss of diurnal rhythmicity with zymosan that had not recovered by day 7.
Cardiac Function
Cardiac function ( Fig. 5 ) measured sequentially by echocardiography under brief anesthesia on days 2, 4, 7, and 14
revealed initial myocardial depression in the zymosan-treated animals, with a significant decrease in stroke volume at day 2 (p = 0.002). Heart rate was initially unchanged but was significantly lower in the zymosan group from day 4 onwards, and this persisted until day 14 (p = 0.006). In a separate group of animals (culled immediately after echocardiography), no difference was seen in any variables measured at 6 hours post zymosan. However, by 24 hours, heart rate was significantly raised and stroke volume had fallen by approximately 50% in the zymosan animals. Cardiac output was correspondingly reduced ( Supplementary Table 3 , Supplemental Digital Content 7, http://links.lww.com/CCM/B186). By 24 hours, core temperature was significantly elevated in the zymosan group (Supplementary Fig. 2a , Supplemental Digital Content 8, http://links.lww.com/CCM/B187).
Muscle Function
Forelimb grip strength was measured on days 0, 2, 5, 8, and 12 (Fig. 6, A and B) . Grip strength in naïve rats progressively increased from day 5 onwards with an 18% ± 7% rise by day 12, whereas grip strength in the zymosan animals initially fell (-14% ± 6% on day 2) and had still not returned to baseline values by day 12. The loss of grip strength seen in the zymosan animals reflected their reduced body mass (Fig. 6B) .
In separate studies, treadmill testing undertaken on days 0, 2, 4, 7, and 14 showed a significant decrease in exercise capacity in the zymosan group that had not recovered by day 14 (Fig. 6C) . In vivo myography performed in these animals at the same timepoints revealed a significant fall in contractile strength at day 2 (Fig. 6D) . Maximum tetanic force measured at the start of the fatigue studies (where a submaximal electrical stimulation was applied) also decreased significantly in the zymosan group at day 2 (Supplementary Fig. 3 , Supplemental Digital Content 9, http://links.lww.com/CCM/B188). The persistently lower mean fatigue index in zymosan-treated animals did not reach statistical significance (p = 0.12) ( Fig. 6E) .
Plasma Electrolyte, Hepatic, Lipid and Hormone biochemistry, and Cytokine Levels
Sham-treated and naïve animals showed similar electrolyte, lipid, and hormone profiles. There was an initial deterioration in renal function, as denoted by significant elevations in plasma urea and creatinine (Fig. 7, A  and B) . Alkaline phosphatase showed a later peak (day 4) in the zymosan group but normalized by day 7, whereas alanine transaminase fell significantly at 24 hours and remained low thereafter (Fig. 7, C and D) . Bilirubin levels did not change (data not shown). Total cholesterol was significantly lower in zymosan-treated animals at 1-2 days post insult, while high-density lipoprotein cholesterol remained suppressed from day 1 to day 7 (Fig. 7, E and F) . Interleukin (IL)-6 was significantly elevated at 6 hours in zymosan-injected animals compared with naïve, but had normalized by day 2 (Fig. 7G) . On the other hand, IL-10 remained elevated throughout (Fig. 7H) .
Plasma leptin and insulin levels showed a similar pattern after zymosan, with an early elevation at 6 hours, but a significant fall from day 2 which had not recovered by day 7 (Fig. 7,  I and J) . There were no significant differences in either plasma glucose or ghrelin levels between groups at any timepoint (data not shown).
Hemoglobin levels in zymosan-treated animals were elevated compared with naïve rats at day 2 (14.8 ± 0.24 g/dL vs 12.9 ± 0.44 g/dL; p < 0.05) ( Supplementary Fig. 2b , Supplemental Digital Content 8, http://links.lww.com/CCM/ B187) but fell to similar levels by day 7 and continued to fall thereafter (days 12 and 14).
Muscle Histology
Muscle from naïve animals was histologically normal with no necrosis or inflammation and less than 1% of fibers showing atrophy or internalized nuclei ( Figs. 8 and 9) . Across both sham and septic groups, gastrocnemius was histologically normal or showed rare isolated atrophic or necrotic fibers. However, soleus demonstrated mild-to-moderate scattered atrophic and necrotic fibers and perimysial inflammation in varying combinations in nine of 10 sham animals. The septic group showed pathological changes from day 2 through day 14 with moderateto-marked pathology in one or more domains (predominantly scattered myofiber atrophy and necrosis), most frequently seen in day 7 samples. None of the septic animals showed complete resolution by day 14, with moderate-to-severe changes persisting in half. Inflammation primarily centered on the perimysium with macrophages predominating and with accompanying edema and focal extension into the fascicles. Regeneration was mostly observed in day 7 and day 14 septic samples, with scattered smaller and mature-sized fibers as well as focally accentuated or prominent circumscribed regeneration. Very early-stage regenerating fibers resembling myotubes were virtually never observed. Examples of histological abnormalities seen in soleus muscle are shown in Figure 8 .
The mean myofiber diameter of gastrocnemius (p = 0.02) and soleus (p < 0.001) was significantly reduced in the zymosantreated group. Maximal change (-12%) was seen for gastrocnemius at day 2, whereas for soleus, a nadir of 15% was seen on both days 7 and 14. In comparison to naïve samples, the spread of myofiber size was smallest in both muscle types on day 2 (Fig. 9 ). 
DISCUSSION
We sought to develop and characterize a long-term zymosan peritonitis model of critical illness and recovery by extensive characterization of cardiovascular, muscle, hormonal, and metabolic profiles. Early loss of body mass, muscle mass, total protein and fat, with reduced food intake, metabolic derangement, and cardiovascular and functional muscle compromise correlated with clinical illness severity. Recovery in body weight and muscle functionality was slow with many aspects of muscle function, metabolic and hormonal profiles not recovering, even after 1-2 weeks. Soleus muscle histology showed persisting inflammation, atrophy, and necrosis, with some evidence of regeneration in the recovery phase. This model thus reflects changes reported in patients (10, 31, 32) and recapitulates the concept of the Persistent Inflammation, Immunosuppression, and Catabolism syndrome (PICS) after critical illness elegantly described by Gentile et al (33) .
As with patients with sepsis, we found considerable heterogeneity in the individual host response. Regardless of an identical insult given to animals of similar age, gender, and rearing, some responded with negligible clinical severity, whereas others became critically ill and even succumbed. Zymosan-treated animals were excluded a priori if their 24-hour clinical severity score was zero or if secondary deterioration occurred after several days of clinical improvement. Unaffected animals maintained near-normal food intake throughout with minimal consequences on body mass, plasma biochemistry, and cardiac function. We previously reported clinical, biochemical, and molecular variability in a 3-day rat model of fecal peritonitis, with distinct hemodynamic and gene transcriptomic profiling as early as 6 hours that enabled clear prognostication (17, 22) .
The choice of species is important in extrapolating findings to human critical illness. Seok et al (34) demonstrated marked transcriptomic differences between mice and humans suffering burn, trauma, and endotoxemic insults. We recently reported that mice become rapidly hypothermic, hypoglycemic, and profoundly hypometabolic within hours of a fecal peritonitis insult; by contrast, the rat phenotype was far more comparable to septic humans (35) . We thus feel the use of rats as a comparative model is valid; indeed, many parallels are seen with prolonged critical illness (33) The focus of this present model was on the recovery phase following critical illness. We, therefore, specifically opted to minimize interventions such as vascular line placement, fluid administration, and antibiotics, though ad libitum access to food and water was permitted. Timepoints were chosen to capture the clinical nadir and subsequent recovery period.
Our zymosan model suffered an initial 10-15% weight loss before recovering to baseline between days 5 and 8. Food intake was low for the first 2 days but gradually increased to normal over the next 3-4 days. These findings were less severe than those reported by Minnaard et al (16) . In conjunction with the weight loss, there was a marked reduction in total body protein and fat mass.
Each degree rise in temperature is associated with a 10-15% increase in oxygen consumption (36) . Notwithstanding an early rise in core temperature that persisted for at least 24 hours in the zymosan group, there was an early marked fall in oxygen consumption (~25-30%) that persisted for several days, with an ongoing loss of diurnal rhythmicity. Although decreased activity levels and food intake contribute to this decrease in metabolic rate, by day 7, there was an obvious improvement in clinical severity and near normalization of food intake. Other mechanisms need to be considered, including decreases in adenosine triphosphate-coupled mitochondrial respiration and a greater degree of uncoupled respiration that would account for the initial pyrexia despite decreased muscular activity and food oxidation (37) (38) (39) . In humans, oxygen consumption rises in the early phase of uncomplicated sepsis, but then normalizes as organ dysfunction develops (40) . In survivors, a rebound increase in oxygen consumption occurs during the recovery phase (40, 41) . In human sepsis, there are many interventions that either increase (e.g., inotropes, feeding, and fluid resuscitation) or suppress (e.g., sedation, mechanical ventilation, and antipyretics) metabolism, but which are avoided in a "purer" laboratory model. This human pattern was not directly reflected in our zymosan model.
The fall in respiratory exchange quotient reflects the shift toward oxidation of endogenous fat and protein. This is due to both the decrease in food intake and to an inflammationrelated shift in substrate utilization. This is consistent with the marked decrease seen in muscle mass and total body fat and protein stores. A similar pattern was seen with plasma leptin and insulin levels in response to zymosan, with an early increase at 6 hours, normalization at 24 hours, and marked and persisting subnormality from day 2 onwards, despite progressive clinical recovery and increased food intake. The early leptin rise may be related to involvement in the acute inflammatory response, while the subsequent fall may reflect reduced body fat stores (42) . Plasma insulin, like leptin, correlates with body fat when fasting and after ingestion of food or carbohydrate (43, 44) . Insulin resistance is a well-recognized feature of critical illness (45) . Peripheral insulin has intrinsic anabolic actions that can prevent muscle protein breakdown (46, 47) . The low levels seen in our model during recovery may partly explain the enduring reduction in muscle mass observed in the zymosan-treated animals. Unlike humans (48) , no change in ghrelin was detected in the septic animals.
The initial rise in hemoglobin following zymosan likely reflects initial hemoconcentration due to volume depletion from decreased fluid intake and increased capillary leak, whereas the subsequent anemia seen after day 7 is probably related to bone marrow suppression and erythropoietin resistance caused by sepsis. The early appearance and disappearance of plasma IL-6, yet an elevated IL-10 level that persisted throughout the 14-day study period, is indicative of a prolonged anti-inflammatory phenotype consistent with the PICS paradigm (33) .
To our knowledge, no temporal assessment has been made of muscle function during sepsis. Treadmill exercise capacity has been assessed in animal models of heart failure (49, 50) , diabetes (51), aging (52, 53) , and skeletal muscle pathophysiology (54) (55) (56) (57) . Motorized rodent treadmills have been used in sepsis models though as a means of determining the impact of endurance training on outcomes (58) (59) (60) (61) . The early and persisting fall in treadmill exercise capacity reflected the decrease in grip strength and the myography fatigue index shown with repetitive twitch. Our in vivo myography technique offers a novel means of monitoring sequential changes in muscle function as it allows full recovery of the animal following assessment while employing the same principles of electrical stimulation and fatigue as described elsewhere. As electrode placement is in the hindlimb muscle bulk, the setup limits determination of individual muscle performance, but is rather more comparable to compound muscle forces that occur physiologically.
Previous sepsis models have used terminal experiments to assess muscle contractility at a single timepoint. Following cecal ligation and puncture, reduced contractile force and increased fatigue were shown in rat soleus at 7 days (7) and Figure 6 . Effect of zymosan on forelimb grip strength, exercise capacity, sequential force generation with increasing electrical stimulation, and fatigue studies. Grip strength was measured at baseline and on days 2, 5, 8, and 12 after injection of IP zymosan (n = 9) or no injection (naïve, n = 5) using a grip strength meter (A). Results corrected for body mass (b) are also shown. Treadmill performance time (C), in vivo myography (D), and change in the maximal tetanic force generated on submaximal electrical stimulation (E) were measured at baseline and 2, 4, and 7 d following zymosan (n = 7-16) and naïve (n = 7-10), with additional animals undertaking treadmill and myography tests on day 14 (zymosan, n = 5-8; naïve, n = 3-4). Data are expressed as mean (± sd). *p < 0.05 vs naïve.
www.ccmjournal.org e93 extensor digitorum longus at 10 days (8) . Here, the distal tendon was attached to a force transducer with complete denervation of surrounding musculature. Minnaard et al (16) assessed neuromuscular function in zymosan peritonitis by direct peroneal nerve stimulation, primarily affecting the tibialis anterior. Reduced torque measurement was seen in zymosan-treated rats compared with controls by day 6 with improvement by day 11, albeit not to preinsult levels. Tibialis anterior is a fast twitch muscle with predominantly type II fibers (62) that causes dorsiflexion. This may be affected differently from muscle groups causing plantar flexion where multiple muscle fiber types are active, in particular, soleus which is predominantly a slowtwitch, mitochondria-rich muscle with a large percentage of type I fibers.
Histopathological analysis revealed tissue damage in the form of macrophage-predominant fascial inflammation, edema, and a necrotizing myopathy consistent with observations in septic humans (10) . Interestingly, gastrocnemius was virtually unaffected, whereas soleus bore the brunt of the pathological changes. Rat gastrocnemius is composed of multiple fiber types with type II subtypes predominating in the white, superficial portion and a higher type I content in the red, deep portion. Importantly, the histopathological changes do not represent an artifact of secondary damage induced by either electromyographic electrode insertion or exercise as samples were also taken from nonexercised, nontested animals and showed similar changes. Despite improvements in functional, biochemical, and metabolic variables, at a cellular level, there was ongoing inflammation, necrosis, atrophy, and regeneration in the septic animals beyond day 7, with considerable variation in severity between individual animals.
The increased expression of MAFbx and MuRF1 strongly suggest involvement of the ubiquitin-proteasome pathway in zymosan-induced muscle mass loss, as previously reported (16) . Increased expression of MAFbx and MuRF1 was demonstrated in C2C12 myotubes incubated for 24 hours with plasma pooled from patients with sepsis at different timepoints in their ICU admission (63) . Importantly, plasma incubation was associated with a concomitant fall in myosin content. We previously reported activation of the ubiquitinproteasome pathway in skeletal muscle biopsies taken from patients with sepsis (64) . As observed for MAFbx and MuRF1, an increase in LC3b, cathepsin B, and cathepsin L mRNA levels paralleled the decrease in muscle mass induced by zymosan injection, implying involvement of the autophagy-lysosome pathway in muscle catabolism. These data agree with previous observations that cathepsin L mRNA and protein level are both increased in skeletal muscle of septic rats (65) . Overall, these data support a role for both ubiquitin-proteasome and autophagy-lysosome-dependent proteolysis in the zymosan septic model. Myostatin expression did not parallel expression of either ubiquitin-proteasome-or autophagy-lysosomerelated genes, suggesting that myostatin signaling is probably not involved in the regulation of these genes.
In summary, we have performed a detailed metabolic, hormonal, immunological, muscle functional, and histological characterization of a long-term rodent model of critical illness induced by IP injection of zymosan, with a novel assessment of muscle functionality. This reflects many, though not all, of the features reported in human critical illness. This model appears useful for investigating changes occurring during critical illness and for assessing putative therapies that may attenuate loss, or enhance recovery, of muscle mass and function. 
